World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Immunology
UK
2026

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Best Scientists 189 437 405 44 42 1661 176724
Immunology 189 23 22 1 1 1581 177513
Medicine 190 255 232 29 28 1655 178992

Paul Emery publications per year

The chart shows the history of publications by Paul Emery between 1982 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Paul Emery published across 44 years, from 1982 to 2025, averaging 40.7 papers a year. Output peaked at 120 publications in 2013. 56 of the 1,792 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1982 to 2025. Vertical axis: number of publications, 0 to 120. Peak 120 publications in 2013. 1982: 1 publication 1983: 0 publications 1984: 3 publications 1985: 2 publications 1986: 2 publications 1987: 2 publications 1988: 1 publication 1989: 5 publications 1990: 3 publications 1991: 7 publications 1992: 14 publications 1993: 19 publications 1994: 18 publications 1995: 9 publications 1996: 12 publications 1997: 11 publications 1998: 18 publications 1999: 32 publications 2000: 23 publications 2001: 46 publications 2002: 32 publications 2003: 48 publications 2004: 55 publications 2005: 51 publications 2006: 57 publications 2007: 61 publications 2008: 49 publications 2009: 50 publications 2010: 80 publications 2011: 83 publications 2012: 76 publications 2013: 120 publications 2014: 88 publications 2015: 82 publications 2016: 106 publications 2017: 103 publications 2018: 87 publications 2019: 75 publications 2020: 77 publications 2021: 53 publications 2022: 31 publications 2023: 44 publications 2024: 28 publications 2025: 28 publications
1982 2025

1,792 publications in total across all disciplines

View publications per year as a table
Paul Emery: publications per year, 1982 to 2025
Year Publications
1982 1
1983 0
1984 3
1985 2
1986 2
1987 2
1988 1
1989 5
1990 3
1991 7
1992 14
1993 19
1994 18
1995 9
1996 12
1997 11
1998 18
1999 32
2000 23
2001 46
2002 32
2003 48
2004 55
2005 51
2006 57
2007 61
2008 49
2009 50
2010 80
2011 83
2012 76
2013 120
2014 88
2015 82
2016 106
2017 103
2018 87
2019 75
2020 77
2021 53
2022 31
2023 44
2024 28
2025 28
Total 1,792
Download as CSV

Paul Emery publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Paul Emery sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 807+ publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 1,581 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100 1,581
Download as CSV

Paul Emery D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Emery sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 157+ D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 189 D-Index — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96 189
Download as CSV

Research.com Recognitions

  • 2026 - Research.com Immunology in United Kingdom Leader Award
  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United Kingdom Leader Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Paul Emery is affiliated with the University of Leeds in the United Kingdom. Their research primarily spans the domain of Medicine, with a focus on Rheumatology and related subfields such as Immunology, Pathology and Forensic Medicine, Hematology, and Genetics.

The scientist's work concentrates on several key topics within medical research, including Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Autoimmune and Inflammatory Disorders Research, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, as well as Systemic Sclerosis and Related Diseases.

Frequent publication venues for Paul Emery include Annals of the Rheumatic Diseases, Lara D. Veeken, RMD Open, The Lancet Rheumatology, and Arthritis Research & Therapy.

The following are some of their recent papers along with publication year and venue:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, 2020, Annals of the Rheumatic Diseases
  • Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia, 2020, The Lancet Rheumatology
  • Rheumatoid arthritis, 2023, The Lancet
  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, 2020, Annals of the Rheumatic Diseases
  • Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity, 2020, Nature Communications

Paul Emery collaborates frequently with several co-authors. Notable among these are Kulveer Mankia, Andrea Di Matteo, Laurence Duquenne, Edward M Vital, and Leticia Garcia-Montoya.

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    P E Lipsky;D M van der Heijde;E W St Clair;D E Furst

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

    Jonathan C W Edwards;Leszek Szczepanski;Jacek Szechinski;Anna Filipowicz-Sosnowska

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  • Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

    Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

    Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman

  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J Braun;R van den Berg;X Baraliakos;H Boehm

  • Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

    R A Luqmani;P A Bacon;R J Moots;B A Janssen

  • Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist

    Barry Bresnihan;José Maria Alvaro‐Gracia;Mark Cobby;Michael Doherty

  • A simplified disease activity index for rheumatoid arthritis for use in clinical practice

    J.S. Smolen;F.C. Breedveld;M.H. Schiff;J.R. Kalden

  • Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

    Gerald B. Appel;Gabriel Contreras;Mary Anne Dooley;Ellen M. Ginzler

  • New therapies for treatment of rheumatoid arthritis

    Josef S Smolen;Daniel Aletaha;Marcus Koeller;Michael H Weisman

  • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

    R N Maini;P C Taylor;J Szechinski;K Pavelka

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

Frequent Co-Authors

Dennis McGonagle
Dennis McGonagle University of Leeds
Richard J. Wakefield
Richard J. Wakefield University of Leeds
Philip G. Conaghan
Philip G. Conaghan University of Leeds
Maxime Dougados
Maxime Dougados Hôpital Cochin
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
John D. Isaacs
John D. Isaacs Newcastle University
Ann W. Morgan
Ann W. Morgan University of Leeds
Mikkel Østergaard
Mikkel Østergaard University of Copenhagen
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Robert Landewé
Robert Landewé University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open rewarding career pathways. Nursing professionals often expand into specialized roles such as Family Nurse Practitioner (FNP) or Psychiatric-Mental Health Nurse Practitioner (PMHNP), which complement immunology knowledge with clinical expertise.

If you’re considering further education, exploring the easiest fnp program can help identify online options that balance rigor and flexibility. Similarly, selecting from the top pmhnp programs ensures access to strong clinical placement opportunities, crucial for hands-on experience.

Cost is also a major consideration. The cheapest online pmhnp programs offer budget-friendly pathways without sacrificing program quality, making advanced education more accessible.

Advanced degrees like the Doctor of Nursing Practice (DNP) can lead to competitive salaries. Understanding how much do dnps make by state can guide your career planning and financial expectations post-degree.

Overall, combining immunology with nursing specialties through these online programs can enhance clinical skills and expand career horizons in healthcare.

Best Scientists Citing Paul Emery

Trending Scientists

Recently Published Articles